BBIO and PFE Related Headlines

Go Back

Apr 28, 2026 02:00PM Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'

Apr 28, 2026 12:14PM Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea'

Apr 28, 2026 11:46AM TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'

Apr 28, 2026 11:41AM RBC Capital on BridgeBio Pharma (BBIO): 'we remain buyers'

Apr 28, 2026 11:25AM Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'

Apr 28, 2026 09:48AM Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term'

Apr 28, 2026 09:38AM Barclays: 'We think dropping the question of '441 validity from the case is a major development'

BBIO and PFE Related Press Releases

Go Back

BBIO and PFE Related SEC Filings

Go Back